Results 11 to 20 of about 27,341 (230)

PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis [PDF]

British medical journal, 2022
Objective To compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant.
Safi U. Khan, Siva H. Yedlapati, Ahmad N. Lone, Q. Hao, G. Guyatt, N. Delvaux, G. Bekkering, P. Vandvik, I. Riaz, Sheyu Li, B. Aertgeerts, N. Rodondi   +11 more
semanticscholar   +2 more sources

Ezetimibe: An Unusual Suspect in Angioedema

Case Reports in Medicine, 2020
We describe a case of new onset angioedema likely due to Ezetimibe therapy in an elderly patient with a prior history of drug-induced bradykinin reactions who had been on the medication for multiple years.
Tiffany Lu, Tarundeep Grewal
doaj   +2 more sources

Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway

Biomedicines
Background: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating ...
Charmy Twala, Sibusiso Malindisa, Chamone Munnik, Selisha Sooklal, Monde Ntwasa   +4 more
doaj   +2 more sources

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects

Drug Design, Development and Therapy, 2017
Chang Hee Kim,1 Hyungmi An,2 Sung Hye Kim,3 Dongseong Shin4 1Department of Urology, Gachon University Gil Medical Center, Incheon, 2Department of Statistics, Seoul National University, Seoul, 3Clinical Development, Navipharm Co., Ltd., Suwon ...
Kim CH, An H, Kim SH, Shin D
doaj   +1 more source

Species Differences in Ezetimibe Glucuronidation

Metabolites
Background: Peclinical and clinical studies have revealed that ezetimibe, an approved cholesterol-absorption inhibitor, is rapidly and extensively metabolized to a more potent metabolite, ezetimibe glucuronide.
Shalom Emmanuel, Eric A. Asare, Ting Du, Huan Xie, Dong Liang, Song Gao   +5 more
doaj   +2 more sources

Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. [PDF]

PLoS ONE, 2015
Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting against atherosclerosis when combined with statin. However, side by side comparison has not been made to evaluate the beneficial effects of ezetimibe alone versus statin. Herein,
Chunmiao Tie, Kanglu Gao, Na Zhang, Songzhao Zhang, Jiali Shen, Xiaojie Xie, Jian-An Wang   +6 more
doaj   +2 more sources

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Vascular Health and Risk Management, 2010
Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse21Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, AustraliaAbstract: High-dose potent statin therapy in ...
Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al   +3 more
doaj   +3 more sources

The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells.

PLoS ONE, 2023
Atherosclerosis and cardiovascular events can be prevented, or treated, using statin therapy, either alone or in combination with ezetimibe. Chronic inflammation, vascular proliferation, and the development of atherosclerosis are also influenced by 25 ...
Ewelina Woźniak, Marlena Broncel, Mateusz Niedzielski, Agnieszka Woźniak, Paulina Gorzelak-Pabiś   +4 more
doaj   +2 more sources

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.

Journal of Clinical Lipidology, 2023
BACKGROUND Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), lipoprotein particles, and apolipoproteins, when added to ...
C. Ballantyne, M. Ditmarsch, J. Kastelein, A. Nelson, D. Kling, Andrew Hsieh, D. Curcio, K. Maki, Michael H. Davidson, Stephen J. Nicholls   +9 more
semanticscholar   +1 more source

Impact on urinary oxalate levels with use of ezetimibe

Endocrinology, Diabetes & Metabolism, 2021
Background Calcium oxalate stones are the most common cause of nephrolithiasis in the United States. Smaller studies of
Christopher L. Trautman, Margaret Van Cleve, Emily A. Sullivan, Colleen T. Ball, Jordan J. Cochuyt, Ivan Porter   +5 more
doaj   +1 more source